Arcellx (ACLX)
(Real Time Quote from BATS)
$62.18 USD
-0.98 (-1.55%)
Updated Jul 24, 2024 02:48 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Price, Consensus and EPS Surprise
ACLX 62.18 -0.98(-1.55%)
Will ACLX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ACLX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ACLX
Alkermes (ALKS) Lags Q2 Earnings Estimates
Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates
ACLX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Beat Estimates
How Arcellx (ACLX) Stock Stands Out in a Strong Industry
Arcellx, Inc. (ACLX) Q4 Earnings and Revenues Surpass Estimates
Other News for ACLX
Decoding 8 Analyst Evaluations For Arcellx
Buy Rating Affirmed on Arcellx Inc for Its Innovative Multiple Myeloma Treatments and Competitive Market Position
Arcellx's Strategic Moves With Anito-Cel Aim To Disrupt Myeloma Market
Small-cap, buy-rated stocks with positive estimate revision factors - BofA
Arcellx Inc: Strong Buy Rating on Potential Breakthrough in Multiple Myeloma Treatment